To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
37 Current newsrss
Trial to assess the benefits of partial Factor VIII inhibition in patients undergoing knee replacement surgery
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402...
ThromboGenics NV and BioInvent International AB announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal...
BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co...
BioInvent International AB (OMXS: BINV) announced that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement...
BioInvent International AB and co-development partner ThromboGenics NV announced that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial...
Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
ThromboGenics NV and co-development partner, BioInvent International, announced the publication of data that highlight for the first time the therapeutic potential of anti-PlGF agents to treat cancer...
Decision taken to advance novel, long-acting anticoagulant into Phase II clinical development
BioInvent International AB and co-development partner ThromboGenics NV announced that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial...
Lead pre-clinical candidate TB- 403 (Anti-PlGF) set to enter the clinic in late 2007
clinical programs are continuing to progress in line with earlier guidance. ThromboGenics' preclinical portfolio currently comprises TB-403 (anti-PlGF, jointly being developed with BioInvent AB, Sweden...
ThromboGenics NV and BioInvent International AB announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB...